Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
BioNTech SE

BioNTech SE (BNTX) Stock Overview

Explore BioNTech SE’s financial performance, market position, analyst ratings, and future outlook.

BNTX●NASDAQ
HealthcareBiotechnology
$116.57
$5.68(5.12%)
U.S. Market opens in 63h 25m

BioNTech SE (BNTX)

Meyka AI Score

Z

Key Financials

Market Cap29.3B
P/E Ratio-14.62
EPS (TTM)$-7.71
ROE-0.09%
Fundamental Analysis

AI Price Forecasts

1 Month$78.59
3 Months$88.01
1 Year Target$109.10

BNTX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of BioNTech SE (NASDAQ: BNTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, BioNTech SE's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of BNTX on the NASDAQ shows an RSI of 79.05, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $109.10 for the NASDAQ listing.

Key metrics behind BioNTech SE's NASDAQ-traded stock include a P/E ratio of -14.62 and a market capitalization of 29.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of BNTX on the NASDAQ.

Price Performance (NASDAQ: BNTX)

1-Day Change
5.12%
5-Day Change
27.08%
1-Month Change
26.25%
3-Month Change
28.20%
6-Month Change
5.83%
Year-to-Date (YTD) Change
22.45%
1-Year Change
5.24%
3-Year Change
-0.82%
5-Year Change
-69.49%
All-Time (Max) Change
718.61%

Contact Information

https://www.biontech.com/de/de/home.html
49 6131 9084 0
An der Goldgrube 12, Mainz, RP, 55131

Company Facts

78,070 Employees
IPO DateOct 10, 2019
CountryDE
Actively Trading

Frequently Asked Questions